# A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome

> **NCT01325740** · PHASE2 · SUSPENDED · sponsor: **Seaside Therapeutics, Inc.** · enrollment: 16 (estimated)

## Conditions studied

- Fragile X Syndrome

## Interventions

- **DRUG:** STX107

## Key facts

- **NCT ID:** NCT01325740
- **Lead sponsor:** Seaside Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2011-05
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 16 (ESTIMATED)
- **Why stopped:** pending further evaluation
- **Last updated:** 2012-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01325740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01325740, "A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT01325740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*